New treatment strategies for proliferative lupus nephritis: Keep children in mind!

Lupus

Volumn 16, Issue 8, 2007, Pages 684-691

  Ranchin, Bruno ^a,b   Fargue, S ^a  

^a UNIVERSITÉ LYON 1   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Children; Glomerulonephritis; Immunosuppression; Lupus; Treatment

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS;

AVASCULAR NECROSIS; CHILD CARE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; GONADAL DISEASE; HUMAN; INFECTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROTOXICITY; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CALCINEURIN; CHILD; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; PEDIATRICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 34548458992     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307079810     Document Type: Review

References (63)

1. Perfumo F, Martini A. Lupus nephritis in children. Lupus 2005; 14: 83-88.
2. Niaudet P, Salomon R. Systemic lupus erythematosus. In Avner ED, Harmon WE, Niaudet P eds. Pediatric nephrology. Lippincott Williams and Wilkins, 2004: 865-886.
3. Baqi N, Moazami S, Singh A, Ahamad H, Balachandra S, Tejani A. Lupus nephritis in children: a longitudinal study of prognosis factors and therapy. J Am Soc Nephrol 1996; 7: 924-932.
4. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136: 243-247.
5. Hagelberg S, Lee Y, Bargman J et al. Long term follow-up of childhood lupus nephritis. J Rheumatol 2002; 29: 2635-2642.
6. Barbano G, Gusmano R, Damasio B et al. Childhood-onset lupus nephritis: a single center experience of pulse intravenous cyclophosphamide therapy. J Nephrol 2002; 15: 123-129.
7. Bogdanovic R, Nikolic V, Pasic S et al. Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr nephrol 2004; 19: 36-44.
8. Wang LC, Yang YH, Lu MY, Chiang BL. Retrospective analysis of the renal outcome of pediatric lupus nephritis. Clin Rheumatol 2004; 23: 318-323.
9. Wong SN, Tse KC, Lee TL et al. Lupus nephritis in Chinese children - a territory-wide cohort study in Hong Kong. Pediatr nephrol 2006; 21: 1104-1112.
10. Lau KK, Jones DP, Hasting MC, Gaber LW, Ault BH. Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children. Pediatr nephrol 2006; 21: 655-662.
11. Lee BS, Cho HY, Kim EJ et al. Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatr nephrol 2007; 22: 222-231.
12. Beresford MW, Davidson JE. Adolescent development and SLE. Best Pract Res Clin Rheumatol 2006; 20: 353-368.
13. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984; 311: 1528-1533.
14. Austin HA, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
15. Flanc RS, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208.
16. Gouley MF, Austin HA, Scott D et al. Methylprednisolone and cyclophosphamide alone or in combination in patients with lupus nephritis. A randomized controlled trial. Ann Intern Med 1996; 123: 549-557.
17. Illei GG, Crane M, Collins L et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
18. Radis CD, Kahl LE, Baker GL et al. Effects of cyclophosphamide on the development of malignancy and on long term survival of patients with rheumatoid arthritis. A 20-year follow-up study. Arthritis Rheum 1995; 38: 1120-1127.
19. Brunner HI, Bishnoi A, Barron AC et al. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus 2006; 15: 198-206.
20. Gutiérrez-Suarez R, Ruperto N, Gastaldi R et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2989-2996
21. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosupressive therapy in lupus nephritis. The Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
22. Houssiau FA, Vasconcelos C, D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Lessons from long-term followup of patients in the Euro-lupus nephritis trial. Arthritis Rheum 2004; 50: 3934-3940.
23. Grootscholten C, Ligtenberg G, Hagen EC et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70: 732-742.
24. Grootscholten C, Bajema IM, Florquin S et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007; 56: 924-937.
25. Tam LS, Li EK, Leung CB et al. Long term treatment of lupus nephritis with ciclosporine A. Q J Med 1998; 91: 573-580.
26. Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005; 68: 813-817.
27. Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclosporine A neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatology 1998; 37: 217-221.
28. Chan TM, Li FK, Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
29. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
30. Fu YF, Liu GL. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporine. Clin Nephrol 2001; 55: 318-321.
31. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28: 2103-2108.
32. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-432.
33. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998; 7: 622-629.
34. Mok CC, Ying KY, Ng WL et al. Long term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006; 119: 355.e25-e33.
35. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677.
36. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002; 206: 519-527.
37. Saito K, Nawata M, Nakayamada S, Tokunaga M, Tsukada J, Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 2003; 12: 798-800.
38. Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003; 12: 783-787.
39. Looney RJ, Anolik JH, Campbell D et al. B Cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
40. Van Vollenhoven RF, Gunnarsson I, Welin-Henriksso E et al. Biopsyverified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004; 33: 423-427.
41. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52: 501-513.
42. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44: 1542-1545.
43. Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression. Pediatr Nephrol 2005; 20: 811-813.
44. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmunity Rev 2006; 5: 18-24.
45. Marks SD, Patey S, Brogan PA et al. B Lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3168-3174.
46. Willems M, Haddad E, Niaudet P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006; 148: 623-627.
47. Smith KGC, Jones RB, Jayne DRW. Long term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis. Arthritis Rheum 2006; 54: 2970-2982.
48. Vignas-Perez M, Hernadez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Therapy 2006; 8: R83.
49. Jacobson SH, van Vollenhoven R, Gunnarsson I. Rituximab-induced long-term remission of membranous lupus nephritis. Nephrol Dial Transplant 2006; 21: 1742-1743.
50. Carroll RP, Brown F, Kerr PG. Anti-CD20 antibody treatment in refractory class IV lupus nephritis. Nephrol Dial Transplant 2007; 22: 291-293.
51. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000; 9: 170-175.
52. Bessant R, Duncan R, Ambler G et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case control study. Arthritis Rheum 2006; 55: 892-899.
53. Mok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50: 2559-2568.
54. Contreras G, Pardo V, Leclercq B et al. Sequential therapy for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
55. Moroni G, Doria A, Mosca M et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006; 1: 925-932.
56. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997; 145: 408-415.
57. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
58. Kavey REW, Allada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients. A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Circulation 2006; 114: 2710-2738.
59. Tse KC, Li FK, Tang S et al. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 2005; 14: 947-952.
60. Kanda H, Kubo K, Tateishi S et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 2005; 14: 288-292.
61. Ruggenenti P. Angiotensin-converting enzyme inhibition and angiotensin II antagonism in non diabetic chronic nephropathies. Semin Nephrol 2004; 24: 158-167.
62. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67: 799-812.
63. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123.